Hospitalized Patients with COPD: Analysis of Prior Treatment

Overview

Journal J Bras Pneumol

Specialty Pulmonary Medicine

Date 2014 Jul 17

PMID 25029645

Citations 6

Authors

Irai Luis Giacomelli

Leila John Marques Steidle

Frederico Fernandes Moreira

Igor Varela Meyer

Ricardo Goetten Souza

Mariangela Pimentel Pincelli

Affiliations

Soon will be listed here.

Abstract

Objective: Although COPD is a prevalent disease, it is undertreated, and there are no available data regarding previous treatment of COPD in Brazil. This study aimed to determine the appropriateness of maintenance treatment in COPD patients prior to their hospitalization and to identify variables associated with inappropriate treatment.

Methods: This was an observational, cross-sectional, analytical study involving 50 inpatients with COPD at two hospitals in the city of Florianópolis, Brazil. The patients completed a questionnaire on parameters related to the maintenance treatment of COPD. Non-pharmacological management and pharmacological treatment were assessed based on the recommendations made by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) in 2011 and by the Brazilian National Ministry of Health in the chronic respiratory diseases section of its Caderno de Atenção Básica (CAB, Primary Care Guidebook).

Results: In most of the patients, the COPD was classified as being severe or very severe. Regarding non-pharmacological management, 33% of the patients were smokers, only 32% had been advised to receive the flu vaccine, 28% had received pneumococcal vaccine, and only 6.5% of the patients in the B, C, and D categories received pulmonary rehabilitation. Regarding GOLD and CAB recommendations, pharmacological treatment was inappropriate in 50% and 74% of the patients, respectively. Based on GOLD recommendations, 38% were undertreated. A low level of education, low income, not receiving oxygen therapy, and not receiving the flu vaccine were associated with inappropriate treatment.

Conclusions: The application of various non-pharmacological management recommendations was unsatisfactory. Regarding the GOLD recommendations, the high rate of inappropriate maintenance treatment was mainly due to undertreatment. In Brazil, even in severe COPD cases, optimizing treatment to achieve greater benefits continues to be a challenge.

Citing Articles

Exploratory analysis of requests for authorization to dispense high-cost medication to COPD patients: the São Paulo "protocol".

Carvalho-Pinto R, Silva I, Navacchia L, Granja F, Marques G, de Cassia Dos Santos Nery T J Bras Pneumol. 2019; 45(6):e20180355.

PMID: 31851214 PMC: 7447535. DOI: 10.1590/1806-3713/e20180355.

Ergojump evaluation of the explosive strength in volleyball athletes pre- and post-fascial treatment.

Buscemi A, Petralia M, Ramaci T, Rapisarda A, Provazza C, Di Corrado D Exp Ther Med. 2019; 18(2):1470-1476.

PMID: 31384337 PMC: 6639914. DOI: 10.3892/etm.2019.7628.

COPD: more treatment will translate to better breathing. Will it?.

Teixeira P, Nogueira M J Bras Pneumol. 2019; 45(1):e20190037.

PMID: 30810647 PMC: 6534400. DOI: 10.1590/1806-3713/e20190037.

Management of COPD within the Brazilian Unified Health Care System in the state of Bahia: an analysis of real-life medication use patterns.

Pinto C, Lemos A, Assuncao-Costa L, Alcantara A, Yamamura L, Souza G J Bras Pneumol. 2019; 45(1):e20170194.

PMID: 30758425 PMC: 6534407. DOI: 10.1590/1806-3713/e20170194.

Imaging and COPD.

Hochhegger B J Bras Pneumol. 2016; 41(6):487-8.

PMID: 26785955 PMC: 4722998. DOI: 10.1590/S1806-37562015000600001.

References

Ernst P, Gonzalez A, Brassard P, Suissa S . Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med. 2007; 176(2):162-6. DOI: 10.1164/rccm.200611-1630OC. View

Bourbeau J, Sebaldt R, Day A, Bouchard J, Kaplan A, Hernandez P . Practice patterns in the management of chronic obstructive pulmonary disease in primary practice: the CAGE study. Can Respir J. 2008; 15(1):13-9. PMC: 2677850. DOI: 10.1155/2008/173904. View

Pincelli M, Grumann A, Fernandes C, Cavalheiro A, Haussen D, Maia I . Characteristics of COPD patients admitted to the ICU of a referral hospital for respiratory diseases in Brazil. J Bras Pneumol. 2011; 37(2):217-22. DOI: 10.1590/s1806-37132011000200012. View

Price L, Billups S, Rice M, Hartsfield C . Investigation of barriers to clinical practice guideline-recommended pharmacotherapy in the treatment of COPD. Pharm Pract (Granada). 2014; 5(2):74-7. PMC: 4155154. DOI: 10.4321/s1886-36552007000200004. View

Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A . Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2003; 361(9356):449-56. DOI: 10.1016/S0140-6736(03)12459-2. View

Clark D, Grove A, Cargill R, Lipworth B . Comparative adrenal suppression with inhaled budesonide and fluticasone propionate in adult asthmatic patients. Thorax. 1996; 51(3):262-6. PMC: 1090636. DOI: 10.1136/thx.51.3.262. View

Rutschmann O, Janssens J, Vermeulen B, Sarasin F . Knowledge of guidelines for the management of COPD: a survey of primary care physicians. Respir Med. 2004; 98(10):932-7. DOI: 10.1016/j.rmed.2004.03.018. View

Menezes A, Macedo S, Noal R, Fiterman J, Cukier A, Chatkin J . Pharmacological treatment of COPD. J Bras Pneumol. 2011; 37(4):527-43. DOI: 10.1590/s1806-37132011000400016. View

Menezes A, Perez-Padilla R, Jardim J, Muino A, Lopez M, Valdivia G . Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study. Lancet. 2005; 366(9500):1875-81. DOI: 10.1016/S0140-6736(05)67632-5. View

10.

Decramer M, Celli B, Kesten S, Lystig T, Mehra S, Tashkin D . Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet. 2009; 374(9696):1171-8. DOI: 10.1016/S0140-6736(09)61298-8. View

11.

Aisanov Z, Bai C, Bauerle O, Colodenco F, Feldman C, Hashimoto S . Primary care physician perceptions on the diagnosis and management of chronic obstructive pulmonary disease in diverse regions of the world. Int J Chron Obstruct Pulmon Dis. 2012; 7:271-82. PMC: 3340113. DOI: 10.2147/COPD.S28059. View

12.

Glaab T, Banik N, Rutschmann O, Wencker M . National survey of guideline-compliant COPD management among pneumologists and primary care physicians. COPD. 2007; 3(3):141-8. DOI: 10.1080/15412550600829299. View

13.

Donner C, Virchow J, Lusuardi M . Pharmacoeconomics in COPD and inappropriateness of diagnostics, management and treatment. Respir Med. 2011; 105(6):828-37. DOI: 10.1016/j.rmed.2010.12.017. View

14.

Tashkin D, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S . A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008; 359(15):1543-54. DOI: 10.1056/NEJMoa0805800. View

15.

Chung K, Caramori G, Adcock I . Inhaled corticosteroids as combination therapy with beta-adrenergic agonists in airways disease: present and future. Eur J Clin Pharmacol. 2009; 65(9):853-71. DOI: 10.1007/s00228-009-0682-z. View

16.

de Queiroz M, Moreira M, Rabahi M . Underdiagnosis of COPD at primary health care clinics in the city of Aparecida de Goiânia, Brazil. J Bras Pneumol. 2013; 38(6):692-9. DOI: 10.1590/s1806-37132012000600003. View

17.

Parker C, Voduc N, Aaron S, WEBB K, ODonnell D . Physiological changes during symptom recovery from moderate exacerbations of COPD. Eur Respir J. 2005; 26(3):420-8. DOI: 10.1183/09031936.05.00136304. View

18.

Barbera J, Roca J, Ferrer A, Felez M, Diaz O, Roger N . Mechanisms of worsening gas exchange during acute exacerbations of chronic obstructive pulmonary disease. Eur Respir J. 1997; 10(6):1285-91. DOI: 10.1183/09031936.97.10061285. View

19.

Jones R, Dickson-Spillmann M, Mather M, Marks D, Shackell B . Accuracy of diagnostic registers and management of chronic obstructive pulmonary disease: the Devon primary care audit. Respir Res. 2008; 9:62. PMC: 2531184. DOI: 10.1186/1465-9921-9-62. View